Treatment completion and tolerability of women with cervical cancer with and without HIV in Botswana.

Authors:

Abstract
5526 Background: Cervical cancer is the leading cause of cancer death for women in Sub-Saharan Africa. HIV increases risk for cervical cancer and concurrent antiretroviral treatment (ART) could increase risk for toxicity of chemoradiation. In the current analysis, we aim to identify differences in treatment toxicities and completion between HIV+ vs. HIV- cervical cancer patients in Botswana treated with radiotherapy (RT). Methods: We prospectively enrolled cervical cancer patients treated with curative RT (+/- chemotherapy). Patients were seen weekly for toxicity monitoring using CTCAE 4 grading. Treatment completion was defined as receiving full dose external beam RT and brachytherapy as prescribed and 4 weekly cycles of cisplatin in < 8 weeks. Results: 190 women were enrolled between 7/2013 and 1/2015. 181 women with complete treatment and HIV data were included in the analysis. 66% (121) of women were HIV+ and presented at a younger age compared to HIV- (median 44 vs. 56 years; p<0.001) and at an earlier stage (HIV- 39% stage II and 47% stage III vs. HIV+ 55% stage II and 31% stage III, p=0.02). Median CD4 count for HIV+ was 469 (range 118-941). 94% of HIV+ patients were on ART. There were no differences between HIV+ vs. HIV- in treatment received and toxicities except renal toxicity in univariate analyses. Only 25% HIV+ vs. 28% HIV- completed treatment. See Table 1. Conclusions: The majority of cervical cancer patients in Botswana are women with well-controlled HIV infection. No significant differences were detected in treatment completion, but HIV+ patients seemed to be at increased risk of renal toxicity. We are further exploring reasons for poor treatment completion in both groups.